Search Results - "Brunt, Murray A"

4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial by Hoskin, Peter, Popova, Biliana, Schofield, Oliver, Brammer, Caroline, Robinson, Martin, Brunt, A Murray, Madhavan, Krishnaswamy, Illidge, Tim, Gallop-Evans, Eve, Syndikus, Isabel, Clifton-Hadley, Laura, Kirkwood, Amy A

“…The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed to compare 24 Gy in 12 fractions (representing the standard of care)…”
Get full text

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial by Cameron, David, Prof, Morden, James P, MSc, Canney, Peter, MD, Velikova, Galina, MD, Coleman, Robert, Prof, Bartlett, John, PhD, Agrawal, Rajiv, FRCR, Banerji, Jane, BHealthSc, Bertelli, Gianfilippo, PhD, Bloomfield, David, MBBS, Brunt, A Murray, Prof, Earl, Helena, Prof, Ellis, Paul, Prof, Gaunt, Claire, BSc, Gillman, Alexa, BSc, Hearfield, Nicholas, BA, Laing, Robert, FRCR, Murray, Nicholas, FRCP, Couper, Niki, BSc, Stein, Robert C, Prof, Verrill, Mark, FRCP, Wardley, Andrew, Prof, Barrett-Lee, Peter, Prof, Bliss, Judith M, Prof

“…Summary Background Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to…”
Get full text

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial by Coles, Charlotte E, Haviland, Joanne S, Kirby, Anna M, Griffin, Clare L, Sydenham, Mark A, Titley, Jenny C, Bhattacharya, Indrani, Brunt, A Murray, Chan, H Y Charlie, Donovan, Ellen M, Eaton, David J, Emson, Marie, Hopwood, Penny, Jefford, Monica L, Lightowlers, Sara V, Sawyer, Elinor J, Syndikus, Isabel, Tsang, Yat M, Twyman, Nicola I, Yarnold, John R, Bliss, Judith M

“…A tumour-bed boost delivered after whole-breast radiotherapy increases local cancer-control rates but requires more patient visits and can increase breast…”
Get full text

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial by Johnston, Stephen RD, Prof, Kilburn, Lucy S, MSc, Ellis, Paul, Prof, Dodwell, David, Prof, Cameron, David, Prof, Hayward, Larry, MD, Im, Young-Hyuck, MD, Braybrooke, Jeremy P, MD, Brunt, A Murray, MD, Cheung, Kwok-Leung, MD, Jyothirmayi, Rema, MD, Robinson, Anne, MD, Wardley, Andrew M, MD, Wheatley, Duncan, MD, Howell, Anthony, Prof, Coombes, Gill, RGN, Sergenson, Nicole, BSc, Sin, Hui-Jung, BSc, Folkerd, Elizabeth, PhD, Dowsett, Mitch, Prof, Bliss, Judith M, Prof

“…Summary Background The optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on…”
Get full text

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer by Poole, Christopher J, Earl, Helena M, Hiller, Louise, Dunn, Janet A, Bathers, Sarah, Grieve, Robert J, Spooner, David A, Agrawal, Rajiv K, Fernando, Indrajit N, Brunt, A. Murray, O'Reilly, Susan M, Crawford, S. Michael, Rea, Daniel W, Simmonds, Peter, Mansi, Janine L, Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C.F, Twelves, Christopher J

“…In women with early breast cancer, adjuvant therapy with epirubicin plus the standard combination of cyclophosphamide, methotrexate, and fluorouracil (CMF) was…”
Get full text

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial by Brunt, A. Murray, Wheatley, Duncan, Yarnold, John, Somaiah, Navita, Kelly, Stephen, Harnett, Adrian, Coles, Charlotte, Goodman, Andrew, Bahl, Amit, Churn, Mark, Zotova, Rada, Sydenham, Mark, Griffin, Clare L, Morden, James P, Bliss, Judith M

“…Abstract Background and purpose FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week…”
Get full text

Ten-year Audit of Melanoma in a Central England Population by HARDWICKE, Joseph, MURRAY BRUNT, A, RYLANDS, Gwen, RAYATT, Sukh

“…The incidence of melanoma in the North Staffordshire region has more than doubled over the last 10 years, and nearly tripled in the "thin" melanoma group (≤ 1…”
Get full text

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial by Goldhirsch, Aron, Prof, Gelber, Richard D, Prof, Piccart-Gebhart, Martine J, Prof, de Azambuja, Evandro, MD, Procter, Marion, MSci, Suter, Thomas M, Prof, Jackisch, Christian, Prof, Cameron, David, Prof, Weber, Harald A, MD, Heinzmann, Dominik, PhD, Lago, Lissandra Dal, MD, McFadden, Eleanor, MA, Dowsett, Mitch, Prof, Untch, Michael, Prof, Gianni, Luca, MD, Bell, Richard, Prof, Köhne, Claus-Henning, Prof, Vindevoghel, Anita, MD, Andersson, Michael, MD, Brunt, A Murray, MD, Otero-Reyes, Douglas, MD, Song, Santai, MD, Smith, Ian, Prof, Leyland-Jones, Brian, PhD, Baselga, Jose, Prof

“…Summary Background Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care…”
Get full text

When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management by Obeng-Gyasi, Samilia, Coles, Charlotte E, Jones, Jade, Sacks, Ruth, Lightowlers, Sara, Bliss, Judith M, Brunt, A Murray, Haviland, Joanne S, Kirby, Anna M, Kalinsky, Kevin

“…In the care of patients with operable breast cancer, there has been a shift toward increasing use of neoadjuvant therapy. There are benefits to neoadjuvant…”
Get more information

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015) by Agrawal, Rajiv K, Alhasso, Abdulla, Barrett-Lee, Peter J, Bliss, Judith M, Bliss, Peter, Bloomfield, David, Bowen, Joanna, Brunt, A Murray, Donovan, Ellen, Emson, Marie, Goodman, Andrew, Harnett, Adrian, Haviland, Joanne S, Kaggwa, Ronald, Morden, James P, Robinson, Anne, Simmons, Sandra, Stewart, Alan, Sydenham, Mark A, Syndikus, Isabel, Tremlett, Jean, Tsang, Yat, Wheatley, Duncan, Venables, Karen, Yarnold, John R

“…Abstract Background and purpose Randomised trials testing 15- or 16-fraction regimens of adjuvant radiotherapy in women with early breast cancer have reported…”
Get full text

Does acupuncture influence the vasomotor symptoms experienced by breast cancer patients taking tamoxifen? by Cumins, Sara M, Brunt, A Murray

Get full text

Abstract P2-15-02: HER2 discordant results in local vs. central testing in the phase 3 nelipepimut-S trial and implementation of Leica Bond Oracle HER2 Immunohistochemistry (IHC) System for low and intermediate levels (1+, 2+) of HER2 protein expression as a companion diagn by Melisko, Michelle, Mittendorf, Elizabeth A, Safina, Sufia, Schenker, Michael, Brunt, Murray A, Litwiniuk, Maria, Mackey, John, Petrakova, Katarina, Alieva, Svitiana, Chance, Lacey, Choy, Gavin S, Ahn, Mark, Hamm, Adamm, Kumar, Sonia, Rugo, Hope S

“…Background : The distinction between HER2-positive (IHC 3+ or 2+ with FISH ratio >/= 2) and not overexpressing HER2 has been the focus of many diagnostic tests…”
Get full text

New Insights on the Pathogenesis and Treatment of Crystal Arthritis by Richette, P., McCarthy, G., Doherty, M., Husted, H., Jameson, S., Reed, M., Murray Brunt, A., Bosworth, A., Buch, M., Symmons, D., Row, I., Dawes, P., Bower, P., Porter, T., Sanders, T., Nio Ong, B., Cheraghi-Sohi, S., Kennedy, A., Morden, A., Rogers, A., Richardson, J., Stevenson, F., Weinman, J., Cordingley, L., Dean, S., Hosking, D. J., Aihie Sayer, A., Compston, J., Mukhtyar, C., Bruce, I., Thachil, J., Wilkie, R., Black, D. C., Gunnyeon, B., Walker, D., Higginbottom, A., Flurey, C. A., Hewlett, S., Ricketts, B., Gordon, C.

Get full text

The safety of intravenous chemotherapy and zidovudine when treating epidemic Kaposi's sarcoma by Brunt, A M, Goodman, A G, Phillips, R H, Youle, M S, Gazzard, B G

“…Patients with epidemic Kaposi's sarcoma, who are often taking zidovudine, may be treated with cytotoxic chemotherapeutic agents. Both cytotoxic chemotherapy…”
Get more information

Salvage mastectomy after failed breast-conserving therapy for carcinoma of the breast by Barr, L C, Brunt, A M, Phillips, R H, Ellis, H

“…The indications, technique and complications of salvage mastectomy in 25 patients with local recurrence after breast-conserving therapy for carcinoma of the…”
Get full text